Amylyx Pharmaceuticals (AMLX) Return on Sales (2021 - 2025)

Amylyx Pharmaceuticals' Return on Sales history runs 5 years deep, the most recent figure standing at 2.24% for Q3 2025.

• In Q3 2025, Return on Sales rose 398.0% year-over-year to 2.24%; the TTM figure through Sep 2025 stood at 2.24% (up 225.0% YoY), while the FY2024 annual figure was 0.03%, down 4.0% from the prior year.
• Return on Sales was 2.24% for Q3 2025 at Amylyx Pharmaceuticals, down from 7.51% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 7.51% in Q2 2025 to a low of 2.82% in Q1 2025.
• Historically, Return on Sales has averaged 0.23% across 5 years, with a median of 0.01% in 2023.
• Biggest YoY gain for Return on Sales was 822 bps in 2025; the steepest drop was 281 bps in 2025.
• A 5-year view of Return on Sales shows it stood at 0.81% in 2021, then surged by 98 bps to 0.02% in 2022, then surged by 102 bps to 0.0% in 2023, then surged by 156372 bps to 0.56% in 2024, then surged by 302 bps to 2.24% in 2025.
• The last three Return on Sales figures came in at 2.24% (Q3 2025), 7.51% (Q2 2025), and 2.82% (Q1 2025), per Business Quant data.